TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 02410399AA		
In Re A	pplication O	f: Hirofumi TACH	IIBANA				
Application No. Filing Date		Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/	551,469	September 30, 2005	unknown	30743	1614	4441	
Title:		OF SCREENING DR	UG WITH THE USE OF 67kDa	LAMININ RE	CEPTOR AND I	DRUG	
			Address to: Commissioner for Paten P.O. Box 1450 Alexandria, VA 22313-14				
			37 CFR 1.97(b)				
1. ⊠	of a nation three mon application	nal application other ths of the date of er n; before the mailing	atement submitted herewith is the than a continued prosecution atry of the national stage as selection on the mest for continued examination united the continued examination united exa	application un t forth in 37 CF nerits, or before	der 37 CFR 1.55 R 1.491 in an ir the mailing of a	3(d); within nternational	
2. 🗆	CFR 1.97 Final Acti	(b), provided that the on under 37 CFR 1	37 CFR 1.97(c) atement submitted herewith is e Information Disclosure State 1.113, a Notice of Allowance n the application, and is accomp	ment is filed b under 37 CFF	efore the mailing R 1.311, or an	g date of a	
	☐ the	statement specified	in 37 CFR 1.97(e);				
			OR				
	☐ the	fee set forth in 37 Cl	FR 1.17(p).				

Docket 02410399AA Serial No.: 10/551,469

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Hirofumi Tachibana Confirmation No.:4441

Serial No. 10/551,469 Group Art Unit: 1614

Filed: September 30, 2005 Examiner: unknown

For: METHOD OF SCREENING DRUG WITH THE USE OF 67kDa LAMININ

RECEPTOR AND DRUG OBTAINED THEREBY

Commissioner for Patents

PO Box 1450

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Under the provisions of 37 C.F.R. §1.97 through §1.98 and pursuant to applicant's duty of disclosure under 37 C.F.R. §1.56, applicant respectfully brings the following documents, cited in the partial European Search Report for the above-identified patent application dated March 13, 2007, and listed on the attached forms PTO-1449, to the attention of the Examiner in charge of the above-identified application.

This citation does not constitute an admission that the references are relevant or material to the claims. They are only cited as constituting related art of which the applicant is aware.

It is respectfully requested that the listed references be formally made of record in the application. Please charge any deficiencies in fees and credit any overpayment of fees to the Attorney's Deposit Account No. 50-2041 (Whitham, Curtis, Christofferson & Cook, P.C.).

Respectfully submitted,

Olga V. Merkoulova

Reg. No. 48,757

Whitham, Curtis & Christofferson, P.C. 11491 Sunset Hills Road, Suite 340

Reston, VA 20190

Tel. (703) 787-9400 Fax. (703) 787-7557

Customer No.: 30743

									
INFORMATION DISCLOSURE CITATION				ATTY DOCKET NO.	APPLICATION NO.				
				0241039 APPLICANT(S)	9AA	10/551,469			
	(Use several sheets if nece.			Hirofumi TACHII	BANA				
				FILING DATE		GROUP ART U	NIT		
			September 30, 2005			1614			
		U.S	S. PATENT	DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	US 6,410,052 B1	06/25/2002	Morre	et al.	424	468	08/10/2000		
		U.S. PATEI	NT APPLIC	ATION PUBLICATIONS	3				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	DATE		CLASS	SUBCLASS FILING D		OATE OPRIATE	
								·····	
		FORI	EIGN PATE	NT DOCUMENTS			T		
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS YES	NO	
							1 120	NO	
					····				
·······	OTHER DOCUM			, Title, Date, Pertin	-	•	1	L	
	A copy of the Supple	ementary Europ	ian Searc	h Report dated Mai	ch 13, 2007, p	ages 1-5			
	Hou et al.: "Effects of MUTATION RESEA								
	NARUMI et al.: "In 37-kDa Taminin bin CANCER ASSOCIA	hibition of experding protein and ATION, TOKYO	rimental r tibody", J), JP, vol.	netastasis of human APANESE JOURN 90, no. 4, April 199	fibrosarcoma AL OF CANC 9, pages 425-43	cells by anti-ro ER RESEARO 1	ecombina CH, JAPA	nt NESE	
EXAMINER	/Minh Tam Davis/ (07/16/2	2008)		DATE CONSIDERED					
*EXAMINER	Initial if reference considered, whether	her or not citation is	s in conform	I nance with MPEP 609; [Oraw line through	citation if not in o	onformanc	e and not	

Form PTO-A820 (also form PTO-1449)

considered. Include copy of this form with next communication to applicant.

		ATTY DOCKET NO.							
IN	FORMATION DISCLOSURE			02410399AA 10/551,469 Hirofumi TACHIBANA					
	(Use several sheets if neces	sary)	FILING	[6	GROUP ART				
			September 3	0, 2005		1614	_		
		U.S. PA	ATENT DOCUMENTS			1			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
		U.S. PATENT A	PPLICATION PUBLICATIONS	.					
*EXAMINER INITIAL	DOCUMENT NUMBER DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
							······································		
		FOREIGN	PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	_ATION NO		
						, = 5			
			William 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,						
	OTHER DOCUME		uthor, Title, Date, Pertine	- ,					
	GEVAROWSKA DO reduce retinal ischem PATHOLOGY, vol. 1	ROTA ET AL.: "S ia and inhibit hypo 60, no. 1, January	ynthetic peptides interact xia-induced retinal neova 2002, pages 307-313	ing with the 67- scularization",	kd laminin r AMERICAN	eceptor ca JOURNA	n L OF		
	TANAKA MASASHI correlates with tumor KOO ET AL.: "Phar OF PHARMACOLO	ET AL.: "Express angiogenesis", CA macological effects GY, AMSTERDAN	ion of the 37-kDa laminin NCER LETTERS, vol. 15 of green tea on the gastro I, NL., vol.500, no. 1-3, O	binding protein 33, no. 1-2, May intestinal systen ctober 1, 2004,	in murine li 29, 2000, pa n'', EUROPI pages 177-18	ung tumor ges 161-16 EAN JOUF	cell 8 RNAL		
EXAMINER /	Minh Tam Davis/ (07/16/200	DATE CONSIDERED	DATE CONSIDERED						
*EXAMINER: Ir	nitial if reference considered, wheth clude copy of this form with next co	er or not citation is in communication to applica	onformance with MPEP 609; D	raw line through ci	tation if not in c	onformance	and not		

Form PTO-A820 (also form PTO-1449)

			ATTY DOCKET NO.			APPLICATION NO.			
INFORMATION DISCLOSURE CITATION					02410399AA 10/551,469				
	(Use several sheets if necessary)			Hirofumi TACHIB	Hirofumi TACHIBANA				
				September 3	0, 2005	GROUP ART	1614		
			U.S. P	ATENT DOCUMENTS					
*EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
INITIAL							IF APPROPRIATE		
:									
•			U.S. PATENT A	APPLICATION PUBLICATIONS					
*EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
INTIAL							IF APPROP	RIATE	
<u>l</u>	<u> </u>		FOREIGI	N PATENT DOCUMENTS	<u> </u>				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	SLATION	
		DOGGMENT NOMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	:								
<u>-</u>	A	OTHER DOCL	JMENTS (Including)	Author, Title, Date, Pertine	ent Pages, Etc		1	<u> </u>	
		KOO et al.: "Phar		f green tean on the gastroi M, NL, vol. 500, No. 1-3, C	- .	•	AN JOUR	NAL	
		OF PHARMACO	LOGY, AMSTERDA	.M, NL, vol. 500, No. 1-3, C	October 1, 200	4, pages 177-1	85		
				WWW.					
EXAMINE	₹ /N	finh Tam Davis/ (07/16	6/2008)	DATE CONSIDERED					
*EXAMINE	R: Initia	I if reference considered what	nether or not citation is in	conformance with MPEP 609: C)raw line through	citation if not in	conformance	and not	

Form PTO-A820 (also form PTO-1449)

considered. Include copy of this form with next communication to applicant.